Genomind Pharmacogenetic Population Health Tool Highlighted in American Journal of Managed Care and 22nd Population Health Colloquium
Innovative approach addresses a huge and costly public health burden
KING OF PRUSSIA, Pa.–(BUSINESS WIRE)–#populationhealth–An innovative population health approach from Genomind was highlighted in a peer-reviewed publication titled, “Predicting Drug-Drug and Drug-Gene Interactions in a Community Pharmacy Population” published in the latest issue of the American Journal of Managed Care (AJMC). The article was co-authored by Stephen Saklad, PharmD, of the University of Texas at Austin and other Genomind colleagues.
Saklad and co-authors reported on an innovative, proprietary approach to population health, with the potential to widely prevent adverse drug events, improve outcomes, and save precious healthcare resources.
The article describes a study in which de-identified prescription data of 4,761 individuals filling prescriptions from a regional community-based pharmacy were used to identify potential drug-drug, drug-gene, and drug-drug-gene interactions.
The analysis randomly allocated genotypes to the population according to each gene’s frequency in the general population, using a statistical technique known as Monte Carlo simulation. Using this method, the authors were able to assign genetic variants to individuals and estimate the risk of drug-gene or drug-drug -gene interactions. They then ordered the individual patients by likelihood of risk. The analysis identifies candidates most likely to benefit from pharmacogenetic (PGx) testing.
The probability of drug-drug-gene interactions (DDGIs) of any impact was correlated with the number of medications. The approximate probability was 76.6%, 85.4%, and 94.2% in patients prescribed 5, 6, or more medications, respectively. Antidepressants, antiemetics, blood products and modifiers, analgesics, and antipsychotics had the highest probability of DDGIs.
Dr. David Krause, Chief Medical Officer of Genomind Inc., and a co-author of the paper, presented the data at the recent 22nd Population Health Colloquium in Philadelphia. Dr. David Nash, Founding Dean Emeritus of the College of Population Health at Thomas Jefferson University and Co-Chairperson of the Colloquium stated “Adverse drug reactions constitute an enormous economic and societal burden. The approach envisioned by Genomind as enumerated in this paper has the potential to make a significant dent in this problem, preventing morbidity for individuals and saving precious health care resources.”
This statement and the publication by AJMC exhibit the growing consensus in support of the clinical utility of pharmacogenetics.
View the publication here.
About Genomind
Genomind is a leading precision health company focused on optimizing the treatment experience for individuals and healthcare providers through actionable genetic insights and innovative health technology. Since its founding, Genomind has expanded beyond its flagship of pharmacogenetic testing to develop a comprehensive portfolio of precision health services for individual and population-level patient care. Built on the foundation of compassionate care and clinical expertise, Genomind is empowering a more targeted and personalized approach to medication management, and a new standard of care.
Contacts
David Krause, MD, Chief Medical Officer – dkrause@genomind.com